🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s CRDL Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+18,354 Shares
Current Position
18,354 Shares
$19,455 Value

Steven Cohen's CRDL Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 18,354 shares of Cardiol Therapeutics Inc. (CRDL) worth $19,455, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Steven Cohen has initiated a new position in CRDL, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Cardiol Therapeutics (CRDL) Holding Value Over Time

Track share changes against reported price movement

Quarterly Cardiol Therapeutics (CRDL) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +18,354 New Buy 18,354 $1.06

Steven Cohen's Cardiol Therapeutics Investment FAQs

Steven Cohen first purchased Cardiol Therapeutics Inc. (CRDL) in Q2 2026, acquiring 18,354 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Cardiol Therapeutics Inc. (CRDL) for 1 quarters since Q2 2026.

Steven Cohen's largest addition to Cardiol Therapeutics Inc. (CRDL) was in Q2 2026, adding 18,354 shares worth $19,455.

According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 18,354 shares of Cardiol Therapeutics Inc. (CRDL), valued at approximately $19,455.

As of the Q2 2026 filing, Cardiol Therapeutics Inc. (CRDL) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Cardiol Therapeutics Inc. (CRDL) was 18,354 shares, as reported at the end of Q2 2026.